one hypothesis suggests that mtwa reflects spatial and temporal heterogeneity or dispersion in the ventricular repolarisation , which could lead to va by means of formation of functional re - entry circuits . despite conflicting results regarding its predictive value and feasibility   , mtwa testing is currently incorporated in the guidelines as a diagnostic tool to improve risk stratification in patients with ischaemic and non - ischaemic severe left ventricular dysfunction   . in this study , we aimed to prospectively evaluate the predictive value of mtwa in a real - life population of icd recipients
significant associations were found with lower lvef ( p  =  0.03 ) , chronic obstructive pulmonary disease ( p  =  0.05 ) , nyha functional class    3 ( p  =  0.02 ) , non - negative mtwa ( p  =  0.05 , fig . 
there was a trend for association between lower lvef and non - negative mtwa.table 1clinical characteristicsallnegativenon - negativeineligiblenumber of patients200488666general  age ( years    sd)63.0 ( 10.3)59.8 ( 11.9)63.0 ( 9.5)65.8 ( 9.8 ) * *  gender ( male)170 ( 84.6)33 ( 68.8)75 ( 87.2)*62 ( 93.9 ) * *  lvef ( %    sd)26.7 ( 12.2)29.1 ( 13.1)25.0 ( 11.2)27.0 ( 12.8)comorbidities  hypertension53 ( 26.4)12 ( 25.0)24 ( 27.9)18 ( 27.3 )  dm47 ( 23.4)11 ( 22.9)14 ( 16.3)22 ( 33.3 )  copd21 ( 10.4)2 ( 4.2)11 ( 12.8)7 ( 10.6 )  cva / tia14 ( 7.0)3 ( 6.2)4 ( 4.7)7 ( 10.6 )  af52 ( 25.9)5 ( 10.4)9 ( 10.5)40 ( 60.6)**indication  primary161 ( 80.5)38 ( 79.2)74 ( 86.0)49 ( 74.2 )  secondary39 ( 19.5)10 ( 20.8)12 ( 14.0)17 ( 25.8)aetiology  ischaemic135 ( 67.2)34 ( 70.8)53 ( 61.6)48 ( 74.2 )  dilated66 ( 32.8)14 ( 29.2)44 ( 38.4)17 ( 25.8)medication  beta - blocker169 ( 84.1)42 ( 87.5)70 ( 81.4)55 ( 83.3 )  acei / arb169 ( 84.1)50 ( 83.3)75 ( 87.2)53 ( 80.3 )  diuretics153 ( 76.1)32 ( 66.7)66 ( 76.7)55 ( 83.3 ) *  amiodarone20 ( 10.0)4 ( 8.3)6 ( 7.0)10 ( 15.2 )  nyha functional class 353 ( 26.8)7 ( 14.6)18 ( 21.2)29 ( 45.3 ) * *  qrs duration ( ms    sd)125 ( 31)115 ( 30)125 ( 28)131 ( 34)**p  <  0.05 and * * p  <  0.01 in comparison with twa negative group 
 lvef left ventricular ejection fraction , dm diabetes mellitus , copd chronic obstructive pulmonary disease , cva cerebrovascular accident , tia transient ischaemic attack , af atrial fibrillation , acei angiotensin - converting enzyme inhibitor , arb angiotensin receptor blocker , nyha new york heart association clinical characteristics * p  <  0.05 and * * p  <  0.01 in comparison with twa negative group 
 lvef left ventricular ejection fraction , dm diabetes mellitus , copd chronic obstructive pulmonary disease , cva cerebrovascular accident , tia transient ischaemic attack , af atrial fibrillation , acei angiotensin - converting enzyme inhibitor , arb angiotensin receptor blocker , nyha new york heart association during a mean follow - up of 38    10  months , 21 patients ( 15.6  % ) reached the primary endpoint of death ( 10 ( 7.5  % ) patients ) and/or appropriate shock therapy ( 11 ( 8.2  % ) patients ) . predictors for the combined endpoint of mortality and appropriate shocks ( table  2 ) were wider qrs duration ( p  =  0.03 ) and chronic obstructive pulmonary disease ( p  =  0.01 ) .